Anti-Mouse CD200 Antibody (OX-90)
Based on 1 Customer Validation
Anti-Mouse CD200 Antibody (OX-90) is an anti-mouse CD200 IgG2a monoclonal antibody. Anti-Mouse CD200 Antibody (OX-90) can reduce immune cell infiltration and T cell function by blocking CD200. Anti-Mouse CD200 Antibody (OX-90) can be used for research on immunology.
For research use only. We do not sell to patients.
- Purity : 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Rat IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
CD200
In Vivo
Anti-Mouse CD200 Antibody (OX-90) (200 μg, i.v., on day 3, 6, 9,12) can weaken the therapeutic effect of anti-PD-L1 mAb in female C57BL/6 mice bearing MC38 or EG7 tumors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×105 Yumm1.7 cells injected C57BL/6 mice[1]
-
Dosage:250 μg
-
Administration:Intraperitoneal injection (i.p.), once every 3 days, from day 7 to day 18
-
Result:Reduced immune cells in tumors and upregulated CCL8 expression.
-
Animal Model:5×105 MC38 or EG7 cells injected female C57BL/6 mice (6-8 weeks)[2]
-
Dosage:200 μg
-
Administration:Intravenous injection (i.v.), on day 3, 6, 9,12
-
Result:Weakened the therapeutic effect of anti-PD-L1 mAb.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo CD200 blockade; in vitro CD200 blockade; Immunohistochemistry (frozen); Immunofluorescenc
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD200 Antibody (OX-90)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Multiplex immunofluorescence IHC
Multiplex immunofluorescence IHC detects multiple protein biomarkers in one tissue section by sequential antibody staining, HRP-mediated tyramide fluorophore deposition, heat-mediated antibody stripping, nuclear counterstaining, multispectral imaging, spectral unmixing, and digital cell phenotyping; TSA deposits fluorophore near the antigen so the fluorescence signal remains after primary and secondary antibodies are removed, enabling repeated staining cycles, including with antibodies from the same host species. Classic FFPE tumor immune-profiling applications use panels such as CD3, CD8, CD68/CD163, FOXP3, PD-1, PD-L1, pancytokeratin, Ki67, and DAPI to identify tumor cells, immune-cell subsets, checkpoint-marker expression, co-expression phenotypes, cell density, and spatial relationships in the tumor microenvironment.
-
Multiplex immunohistochemistry
Multiplex immunohistochemistry (mIHC), also known as tyramide dignal amplification (TSA), is an enzymatic detection method that uses horseradish peroxidase (HRP) to perform high-density in-situ labeling of target proteins or nucleic acids.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Talebian F, et al. CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma. Front Cell Dev Biol. 2021 Oct 8;9:739816. [Content Brief]
[2]. Wang X, et al. CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. Sci Transl Med. 2023 Jan 18;15(679):eabn5029. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)